ME00482B - Čvrste farmaceutske kompozicije koje sadrže pregabalin sredstvo za formiranje matriksa i sredstvo za bubrenje - Google Patents

Čvrste farmaceutske kompozicije koje sadrže pregabalin sredstvo za formiranje matriksa i sredstvo za bubrenje

Info

Publication number
ME00482B
ME00482B MEP-2008-761A MEP76108A ME00482B ME 00482 B ME00482 B ME 00482B ME P76108 A MEP76108 A ME P76108A ME 00482 B ME00482 B ME 00482B
Authority
ME
Montenegro
Prior art keywords
matrix forming
once daily
agent
pharmaceutical compositions
solid oral
Prior art date
Application number
MEP-2008-761A
Other languages
English (en)
French (fr)
Inventor
Howard Norman Bockbrader
Yun Hyung Cho
Santiago Steven Diaz
Majid Mahjour
Thomas Daniel Reynolds
Pushpa Ganapathi Shao
Zezhi Jesse Shao
Jiansheng Wan
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37965070&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME00482(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ME00482B publication Critical patent/ME00482B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Opisana je čvrsta farmaceutska kompozicija koja sadrži pregabalin. Kompozicija uključuje sredstvo za formiranje matriksa i sredstvo za bubrenje i pogodna je za oralnu administraciju jedanput dnevno. Primeri sredstava za formiranje matriksa uključuju smeše polivinl acetata i polivinilpirolidona, a primeri sredstava za bubrenje uključuju umrežene polimare polivinilpirolidona
MEP-2008-761A 2005-11-02 2006-10-23 Čvrste farmaceutske kompozicije koje sadrže pregabalin sredstvo za formiranje matriksa i sredstvo za bubrenje ME00482B (me)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73258905P 2005-11-02 2005-11-02
PCT/IB2006/003063 WO2007052125A2 (en) 2005-11-02 2006-10-23 Solid oral pharmaceutical compositions for once daily dosing containing pregabalin, a matrix forming agent and a swelling agent

Publications (1)

Publication Number Publication Date
ME00482B true ME00482B (me) 2011-10-10

Family

ID=37965070

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2008-761A ME00482B (me) 2005-11-02 2006-10-23 Čvrste farmaceutske kompozicije koje sadrže pregabalin sredstvo za formiranje matriksa i sredstvo za bubrenje

Country Status (34)

Country Link
US (11) US20070269511A1 (me)
EP (1) EP1945186B1 (me)
JP (1) JP4334610B2 (me)
KR (1) KR101012533B1 (me)
CN (1) CN101330907B (me)
AP (1) AP2008004465A0 (me)
AR (1) AR058175A1 (me)
AU (1) AU2006310217B2 (me)
BR (1) BRPI0618211B8 (me)
CA (1) CA2628200C (me)
CR (1) CR9950A (me)
DK (1) DK1945186T3 (me)
DO (1) DOP2006000241A (me)
EA (1) EA012377B1 (me)
EC (1) ECSP088422A (me)
ES (1) ES2449231T3 (me)
GT (1) GT200600474A (me)
HK (1) HK1126394A1 (me)
IL (1) IL190827A (me)
MA (1) MA30135B1 (me)
ME (1) ME00482B (me)
NL (1) NL2000281C2 (me)
NO (1) NO20081816L (me)
NZ (1) NZ567414A (me)
PE (1) PE20070693A1 (me)
PL (1) PL1945186T3 (me)
PT (1) PT1945186E (me)
RS (1) RS20080181A (me)
SI (1) SI1945186T1 (me)
TN (1) TNSN08194A1 (me)
TW (1) TWI330080B (me)
UY (1) UY29890A1 (me)
WO (1) WO2007052125A2 (me)
ZA (1) ZA200803115B (me)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100491282B1 (ko) 1996-07-24 2005-05-24 워너-램버트 캄파니 엘엘씨 통증 치료용 이소부틸가바 및 그의 유도체
ES2380010T3 (es) * 2007-10-16 2012-05-07 Pharmathen S.A. Composición farmacéutica mejorada que contiene un anticonvulsivante derivado de la pirrolidona y método para su preparación
WO2009080365A1 (en) * 2007-12-21 2009-07-02 Synthon B.V. Pregabalin salts
MX2011000136A (es) * 2008-07-09 2011-05-25 Melaleuca Inc Complejo de polisacarido de aminoacido mineral.
WO2010143052A1 (en) 2009-06-12 2010-12-16 Micro Labs Limited Novel pharmaceutical compositions containing pregabalin
WO2010150221A1 (en) 2009-06-25 2010-12-29 Wockhardt Research Centre Taste masked pharmaceutical compositions of pregabalin
KR101317592B1 (ko) * 2009-10-28 2013-10-15 씨제이제일제당 (주) 프레가발린, 폴리에틸렌옥사이드 및 폴리비닐알코올-폴리에틸렌글리콜 그라프트 공중합체를 함유하는 위체류형 서방성 제제
CN104224737A (zh) * 2010-02-24 2014-12-24 硕腾有限责任公司 兽医组合物
HU230031B1 (hu) * 2010-03-01 2015-05-28 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Pregabalint és izomaltot tartalmazó stabilizált gyógyszerkészítmény
AU2011236548A1 (en) * 2010-04-07 2012-11-01 Lupin Limited Controlled release pharmaceutical compositions of tapentadol
EP2389933A1 (en) 2010-05-25 2011-11-30 Sanovel Ilac Sanayi ve Ticaret A.S. Controlled-Release Pregabalin Compositions
TR201005241A1 (tr) * 2010-05-25 2012-01-23 Sanovel �La� San. Ve T�C. A.�. Kontrollü salım sağlayan pregabalin solüsyon formülasyonu.
EP2389934A1 (en) 2010-05-25 2011-11-30 Sanovel Ilac Sanayi ve Ticaret A.S. Controlled-Release Tablet Formulations of Pregabalin
WO2011151708A1 (en) 2010-06-01 2011-12-08 Rubicon Research Private Limited Gastroretentive dosage forms of gaba analogs
BR112013000190A2 (pt) * 2010-07-06 2017-11-07 Gruenenthal Gmbh formas de dosagem de retenção gástrica compreendendo um análogo de gaba e um opioide
EP2415460A1 (de) * 2010-08-03 2012-02-08 ratiopharm GmbH Orale Darreichungsform von Pregabalin
US20130280324A1 (en) * 2010-09-17 2013-10-24 Panacea Biotec Ltd. Sustained release pharmaceutical compositions comprising pregabalin
EP2645997B1 (en) 2010-12-02 2022-08-10 UCB Pharma GmbH Once daily formulation of lacosamide
EA017542B1 (ru) * 2011-05-24 2013-01-30 Плива Кроэйша Лтд. Стабильная фармацевтическая композиция, содержащая прегабалин, капсула, ее содержащая, способ получения и применение
US20140161880A1 (en) * 2011-07-26 2014-06-12 Yuhan Corporation Sustained release tablet comprising pregabalin through two-phase release-controlling system
CN102908327B (zh) * 2011-08-05 2015-03-11 江苏恒瑞医药股份有限公司 伊伐布雷定或其可药用盐的缓释制剂
KR101438546B1 (ko) * 2011-08-26 2014-09-17 근화제약주식회사 프레가발린을 포함하는 서방성 제제
WO2013114281A1 (en) 2012-01-30 2013-08-08 Ranbaxy Laboratories Limited Pregabalin gr tablets
CA2863376A1 (en) 2012-01-30 2013-08-08 Ranbaxy Laboratories Limited Gastroretentive tablets
CN102743357A (zh) * 2012-06-26 2012-10-24 严轶东 一种普瑞巴林胃内泡腾漂浮缓释制剂及其制备方法
EP2908803A1 (en) 2012-10-16 2015-08-26 Ranbaxy Laboratories Limited Osmotic floating tablets
WO2015114655A2 (en) * 2014-01-21 2015-08-06 Intas Pharmaceuticals Limited Modified release tablet of pregabalin
US20160338949A1 (en) 2014-01-28 2016-11-24 Sun Pharmaceutical Industries Limited Stabilized gastroretentive tablets of pregabalin
KR102221846B1 (ko) * 2014-04-07 2021-02-26 영진약품 주식회사 안정성이 개선된 프레가발린을 함유하는 약제학적 조성물 및 이의 제조방법
WO2016062182A1 (zh) * 2014-10-24 2016-04-28 江苏恒瑞医药股份有限公司 一种普瑞巴林缓释制剂
CN104906064B (zh) * 2015-05-15 2017-12-22 中国药科大学 一种普瑞巴林胃漂浮缓释片剂及其制备方法
US9747110B2 (en) * 2015-05-20 2017-08-29 Altera Corporation Pipelined cascaded digital signal processing structures and methods
JP2018520112A (ja) * 2015-05-26 2018-07-26 オディディ，イサ 制御持続放出プレガバリン
CN104840443B (zh) * 2015-05-27 2018-04-27 齐鲁制药有限公司 含活性成分普瑞巴林的药物组合物
US20180344649A1 (en) 2015-09-29 2018-12-06 Acorda Therapeutics, Inc. Sustained release compositions of 4-aminopyridine
CA3030105A1 (en) * 2016-07-17 2018-01-25 Mapi Pharma Ltd. Extended release dosage forms of pregabalin
JP6919119B2 (ja) * 2017-01-23 2021-08-18 日新製薬株式会社 ３位が置換されたγ−アミノ酪酸誘導体を含有する圧縮固形医薬組成物。
JP2019142834A (ja) * 2017-07-31 2019-08-29 大原薬品工業株式会社 プレガバリン並びに好適な賦形剤を含有する固形製剤
WO2019146642A1 (ja) * 2018-01-24 2019-08-01 大原薬品工業株式会社 γ－アミノ酪酸誘導体含有錠剤の化学的安定性を改善する方法
WO2019238068A1 (zh) * 2018-06-13 2019-12-19 北京泰德制药股份有限公司 一种普瑞巴林缓释组合物及其制备方法
CN111053749B (zh) * 2018-10-16 2022-07-15 北京泰德制药股份有限公司 一种普瑞巴林缓释组合物及其制备方法
CN110585153A (zh) * 2018-06-13 2019-12-20 北京泰德制药股份有限公司 一种普瑞巴林缓释组合物及其制备方法
CA3105212A1 (en) * 2018-06-28 2020-01-02 Mylan Inc. Pregabalin extended-release formulations
CN109044981B (zh) * 2018-08-07 2021-02-19 广州帝奇医药技术有限公司 一种普瑞巴林胃漂浮型缓释片及其制备方法
RS64394B1 (sr) 2019-07-03 2023-08-31 Alvogen Inc Tablete pregabalina sa kontrolisanim otpuštanjem, postupak njihove proizvodnje i način upotrebe
CN110974798A (zh) * 2019-12-19 2020-04-10 江苏优仿医药科技有限公司 药物组合物、缓释片剂及其制备方法
EP4309648A1 (en) * 2021-03-17 2024-01-24 Shanghai Yonsun Biotechnology Co., Ltd. Lacosamide pharmaceutical composition, preparation method for same, and applications thereof
CN113577036B (zh) * 2021-05-31 2023-04-04 石药集团欧意药业有限公司 一种普瑞巴林胃漂浮缓释片及其制备方法
GB2624861A (en) * 2022-11-28 2024-06-05 Orbit Pharma Ltd Sustained release pharmaceutical compositions comprising pregabalin or pharmaceutically acceptable salts thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0124363B1 (en) 1983-05-02 1990-12-19 Diamond Scientific Co. Photochemical decontamination treatment of whole blood or blood components
DE3928183A1 (de) 1989-08-25 1991-02-28 Goedecke Ag Lactamfreie cyclische aminosaeuren
US6197819B1 (en) * 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
US5616793A (en) * 1995-06-02 1997-04-01 Warner-Lambert Company Methods of making (S)-3-(aminomethyl)-5-methylhexanoic acid
US5637767A (en) * 1995-06-07 1997-06-10 Warner-Lambert Company Method of making (S)-3-(aminomethyl)-5-methylhexanoic acid
IT1282650B1 (it) 1996-02-19 1998-03-31 Jagotec Ag Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici
US6271278B1 (en) 1997-05-13 2001-08-07 Purdue Research Foundation Hydrogel composites and superporous hydrogel composites having fast swelling, high mechanical strength, and superabsorbent properties
PT1003476E (pt) 1997-08-11 2005-05-31 Alza Corp Forma de dosagem de agente activo de libertacao prolongada adaptada para retencao gastrica
IN186245B (me) * 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
ID26395A (id) 1998-05-15 2000-12-21 Warner Lambert Comapny Turunan asam gamma-aminobutirat yang mengandung komposisi padat dan proses pembuatannya
EP1077692B1 (en) 1998-05-15 2004-07-28 Warner-Lambert Company LLC Amino acid stabilized gabapentin and pregabalin preparations and process for preparing the same
SI1250311T1 (en) * 2000-01-27 2004-10-31 Warner-Lambert Company Asymmetric synthesis of pregabalin
DE10014588A1 (de) * 2000-03-27 2001-10-04 Basf Ag Wirkstoffhaltige Schwimmformen enthaltend Polyvinylacetat und Polyvinylpyrrolidon, deren Verwendung und Herstellung
WO2001097612A1 (en) 2000-06-16 2001-12-27 Teva Pharmaceutical Industries Ltd. Stable gabapentin containing more than 2o ppm of chlorine ion
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
JP2004501190A (ja) 2000-06-23 2004-01-15 テバ　ファーマシューティカル　インダストリーズ　リミティド 治療薬の胃部保留および制御された放出のための急速膨張する組成物とその組成物を含む剤形
CA2356829A1 (en) * 2000-09-22 2002-03-22 Warner-Lambert Company Method for treating asthma using pregabalin
US7056951B2 (en) 2000-09-26 2006-06-06 Mutual Pharmaceutical Co., Inc. Stable solid dosage forms of amino acids and processes for producing same
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
CA2537837A1 (en) * 2003-09-11 2005-03-24 Xenoport, Inc. Treating and/or preventing urinary incontinence using prodrugs of gaba analogs
JP2007509971A (ja) 2003-10-31 2007-04-19 アルザ・コーポレーシヨン メトホルミンの増加された吸収のための組成物及び投与形態物

Also Published As

Publication number Publication date
US20140163103A1 (en) 2014-06-12
US20170348420A1 (en) 2017-12-07
WO2007052125A3 (en) 2007-09-07
US20150352066A1 (en) 2015-12-10
IL190827A (en) 2012-08-30
AP2008004465A0 (en) 2008-06-30
GT200600474A (es) 2007-06-08
DOP2006000241A (es) 2007-05-31
IL190827A0 (en) 2008-12-29
ES2449231T3 (es) 2014-03-18
BRPI0618211A2 (pt) 2011-08-23
US20130303618A1 (en) 2013-11-14
UY29890A1 (es) 2007-05-31
WO2007052125A2 (en) 2007-05-10
KR101012533B1 (ko) 2011-02-07
NO20081816L (no) 2008-05-08
PE20070693A1 (es) 2007-08-11
DK1945186T3 (en) 2014-03-17
CR9950A (es) 2008-05-28
EP1945186A2 (en) 2008-07-23
US9144559B2 (en) 2015-09-29
TNSN08194A1 (fr) 2009-10-30
CA2628200A1 (en) 2007-05-10
CN101330907A (zh) 2008-12-24
TWI330080B (en) 2010-09-11
US20120029081A1 (en) 2012-02-02
CN101330907B (zh) 2012-08-29
PL1945186T3 (pl) 2014-05-30
JP2009514847A (ja) 2009-04-09
KR20080059427A (ko) 2008-06-27
NL2000281A1 (nl) 2007-05-03
ECSP088422A (es) 2008-05-30
AU2006310217B2 (en) 2012-08-16
SI1945186T1 (sl) 2014-03-31
RS20080181A (en) 2009-07-15
US20120232149A1 (en) 2012-09-13
CA2628200C (en) 2011-01-25
PT1945186E (pt) 2014-03-06
US20170136125A1 (en) 2017-05-18
US20160250147A1 (en) 2016-09-01
EA200800931A1 (ru) 2008-10-30
EP1945186B1 (en) 2014-01-22
NL2000281C2 (nl) 2007-08-07
ZA200803115B (en) 2009-09-30
US20070269511A1 (en) 2007-11-22
US20130102675A1 (en) 2013-04-25
NZ567414A (en) 2011-09-30
HK1126394A1 (en) 2009-09-04
AU2006310217A1 (en) 2007-05-10
MA30135B1 (fr) 2009-01-02
AR058175A1 (es) 2008-01-23
US20150094371A1 (en) 2015-04-02
US10022447B2 (en) 2018-07-17
TW200803831A (en) 2008-01-16
US8945620B2 (en) 2015-02-03
JP4334610B2 (ja) 2009-09-30
BRPI0618211B1 (pt) 2020-11-17
BRPI0618211B8 (pt) 2021-05-25
EA012377B1 (ru) 2009-10-30

Similar Documents

Publication Publication Date Title
ME00482B (me) Čvrste farmaceutske kompozicije koje sadrže pregabalin sredstvo za formiranje matriksa i sredstvo za bubrenje
EA200901393A1 (ru) Фармацевтическая композиция, содержащая гестагены и/или эстрогены и 5 метил-(6s)-тетрагидрофолат
BRPI0417717A (pt) composto, composição farmacêutica, e, uso de um composto
HRP20080564T3 (en) Dihydrotetrabenazines and pharmaceutical compositions containing them
NO20011471D0 (no) Nye orale vedvarende frigivelsesformuleringer
DK1480624T3 (da) Farmaceutisk tablet
DE60205749D1 (de) Oral anzuwendende arzneizusammensetzungen mit gesteuerter wirkstoffabgabe
DE602004011398D1 (de) Direkt komprimierbare pharmazeutische zusammensetzung für die orale verabreichung von cci-779
WO2007143163A3 (en) Pharmaceutical compositions for sustained release of phenyephrine
ATE399537T1 (de) Pharmazeutische zusammensetzungen mit atorvastatin, hergestellt ohne granulation
BRPI0717369A2 (pt) Composto, medicamento, composição farmacêutica que o contém e uso do composto.
ATE505203T1 (de) Pharmazeutische kombination aus aliskiren und valsartan
AU2003230189A1 (en) Oral controlled release pharmaceutical composition containing metaxalone as active agent
WO2008081829A1 (ja) 難水溶性薬物の溶解性維持用アミノアルキルメタアクリレートコポリマーｅ
WO2007009691A3 (en) Combination of substituted pyrazolines and anti -addictive agent
EP1584335A3 (en) Active substance combination comprising a carbinol composition and an opioid
DE602006016621D1 (de) Olanzapin enthaltende pharmazeutische zusammensetzung
EP1680098A4 (en) DELAYED RELEASE OF POSITIVELY-LOADED PHARMACOLOGICALLY EFFECTIVE MOLECULES FROM A POLYMER-CONTAINING MATRIX WITH POLARIZED OXYGENATOMES
DK1537132T3 (da) Salt af mortin-6-glucuronid
TW200514571A (en) Pharmaceutical composition with improved solubility and fluidity
PT1499278E (pt) Forma de dosagem farmaceutica de libertacao imediata compreendendo tibolona polimorfa
SV2006002224A (es) Composicion farmaceutica ref. bhco41368-sv
TW200621224A (en) Pharmaceutical composition
AU2003202550A1 (en) Pharmaceutical formulations with modified release
EA200501262A1 (ru) Композиция с пролонгированным высвобождением венлафаксина